Express News | INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
Maxim Group analyst Jason McCarthy maintains $INmune Bio(INMB.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 26.4% and a
Inmune Bio's Clinical Advancements Secure Buy Rating From Analyst Jason McCarthy
INmune Highlights Publication Titled 'Proteomic and Phenotypic Characteristics of Memory-like Natural Killer Cells for Cancer Immunotherapy'
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune in the Journal for ImmunoTherapy of Cancer
INmune and Elevai Labs Amend Licensing Deal